Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
Authors
Keywords
Bevacizumab, Hypertension, Metastatic colorectal cancer, Vascular endothelial growth factor
Journal
World Journal of Surgical Oncology
Volume 11, Issue 1, Pages 306
Publisher
Springer Nature
Online
2013-11-28
DOI
10.1186/1477-7819-11-306
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
- (2013) Istvan Lang et al. LANCET ONCOLOGY
- Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs
- (2012) Giuseppe Lombardi et al. ANTI-CANCER DRUGS
- Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma
- (2012) Todd D. Tillmanns et al. GYNECOLOGIC ONCOLOGY
- Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
- (2012) Cornelia Schuster et al. PLoS One
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
- (2011) Alfonso De Stefano et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- An Observational Study of Bevacizumab-Induced Hypertension as a Clinical Biomarker of Antitumor Activity
- (2011) O. Mir et al. ONCOLOGIST
- Hypertension as a Predictive Factor of Effect of Bevacizumab in Treatment of Colorectal Cancer
- (2011) Yuya HORINOUCHI et al. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
- Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis
- (2010) Elena Galfrascoli et al. DIGESTIVE AND LIVER DISEASE
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
- (2008) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Updated Results From the BICC-C Study
- (2008) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now